TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02973386

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMRT combine with cisplatin concurrent chemotherapy
Description: Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Description: Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
Study: NCT02250846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: egfr-TKI treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKI
Description: egfr-TKI treatment
Study: NCT01611714

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit-feedback
Description: Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audit-feedback
Description: Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template.
Study: NCT01149096

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Donation
Description: Undergo bone marrow harvest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Donation
Description: Undergo bone marrow harvest

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT04701008

Intervention type: DRUG
Intervention: Ketamine
Description: IV ketamine - 10mg bolus may be repeated repeated 2-3 times depending on clinical judgement
Study: NCT03964727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: Administered intravenously
Study: NCT03939624

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter 2 (SGLT2) inhibitors
Description: Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.

Intervention type: DRUG
Intervention: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Description: Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
Study: NCT00834977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine-benazepril 10 mg-20 mg capsules
Description: 1 x 10-20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotrel® 10 mg-20 mg capsule
Description: 1 x 10-20 mg
Study: NCT02254863

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DUOC-01
Description: Intrathecal administration of DUOC-01
Study: NCT04197934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood samples
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood samples
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood samples
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - blood samples
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - CSF samples
Description: Undergo collection of CSF samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection - CSF samples
Description: Undergo collection of CSF samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR/EGFRvIII Inhibitor WSD0922-FU
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR/EGFRvIII Inhibitor WSD0922-FU
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR/EGFRvIII Inhibitor WSD0922-FU
Description: Given PO
Study: NCT03727438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: The Health Education Control condition is comprised of two components: 1) weekly reading from a health education manual, and 2) weekly telephone-based nurse support contacts across a 8 week period. At the end of the study, participants in the Health Education arm will be offered assistance for their sleep complaints, as needed, through the Durham Behavioral Sleep Medicine clinic.
Study: NCT00432666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (Xeomin)
Description: incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02247557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome encapsulated BoNT-A
Description: Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
Study: NCT04197934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR/EGFRvIII Inhibitor WSD0922-FU
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT04195945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Granulocyte Colony-Stimulating Factor
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01500733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI 32765
Description: 420 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCI 32765
Description: 420 mg daily
Study: NCT02101775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03270982

Intervention type: DEVICE
Intervention: Comprehensive SRS Replacement
Description: This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
Study: NCT04007692

Intervention type: PROCEDURE
Intervention: Esophageal stent placement
Description: Exposure of interest is standard of care esophageal stent placement
Study: NCT02247557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX 200U in normal saline
Description: BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (N/S) 50ml in single intravesical instillation
Study: NCT03982355

Intervention type: DEVICE
Intervention: DRS probe
Description: The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe

Intervention type: DEVICE
Intervention: DRS probe
Description: The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
Study: NCT02365649

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-494
Description: Oral Dosing
Study: NCT04421053

Intervention type: BEHAVIORAL
Intervention: prenatal care for women with GDM
Description: we conduct prenatal care for GDM pregnancies through both prenatal clinic and app.
Study: NCT02226367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin hydrochloride
Description: study drug arm prazosin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: study drug arm placebo
Study: NCT03904394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
Study: NCT03975010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch
Description: This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch
Description: This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Patch
Description: This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7\~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal.
Study: NCT04240210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symtuza
Description: The study is a prospective cohort analysis of change in adherence, tolerability and safety of subjects who reports poor adherence to ART due to intolerance/side effects from integrase inhibitor containing regimens when they are switched to DRV/COB/FTC/TAF and monitored for 4 months.
Study: NCT02227914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oprozomib
Description: Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Study subjects will receive sorafenib tablets twice a day for Days 1-28
Study: NCT03366610

Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study: NCT02662673

Intervention type: DEVICE
Group type: OTHER
Intervention: Focal High Intensity Focused Ultrasound (HIFU) treatment
Description: Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
Study: NCT01648465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
Study: NCT01740167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health promotion lifestyle program
Description: Individual counseling, once a month, total 3 times.
Study: NCT02164253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: 30 mg/kg per day, oral use
Study: NCT03710187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg IV Q6h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 50 mg IV Q6h
Study: NCT00231816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (concomitant)
Description: a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Influenza Vaccine
Description: a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Influenza Vaccine
Description: a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX™ (Nonconcomitant)
Description: Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
Study: NCT02079896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexaptepid pegol (NOX-H94)
Description: anti-hepcidin L-RNA-aptamer (Spiegelmer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexaptepid pegol (NOX-H94)
Description: anti-hepcidin L-RNA-aptamer (Spiegelmer)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02991183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
Study: NCT03715556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% physiological solution
Description: Administration of 0.9% physiological solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% physiological solution
Description: Administration of 0.9% physiological solution.
Study: NCT02192580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
Study: NCT00412334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1200-1600mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1200-1600mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000-1200mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000-1200mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc twice weekly
Study: NCT03696836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trammpolin® meniscus prosthesis
Description: Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
Study: NCT03800381

Intervention type: OTHER
Intervention: Observational PK study
Description: The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.

Intervention type: OTHER
Intervention: Observational PK study
Description: The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
Study: NCT04089748

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Intervention type: COMBINATION_PRODUCT
Intervention: neoadjuvant chemotherapy with cisplatine
Description: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
Study: NCT02521285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies